Latest Breaking News On - Myeloid disorders - Page 1 : comparemela.com

Investigators Set to Explore Selinexor Monotherapy or Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Johno mascarenhasDynamic international prognostic scoring systemAdult leukemia programTisch cancer instituteMyeloproliferative disorders programIcahn school of medicine at mount sinaiIcahn schoolMount sinaiBlood cancersMyeloid disordersMyeloproliferative disordersMyelofibrosis symptom assessment formAdv hematolJak inhibitor naive myelofibrosisXport mf 044Xport mf 034

Dr Mascarenhas on the Use of Selinexor in Myelofibrosis

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

John mascarenhasTisch cancer instituteIcahn school of medicineIcahn schoolMount sinaiBlood cancersMyeloid disordersOnclive tvReviewing research efforts seeking to raise the bar in myelofibrosis

Hôpital Saint-Louis Implements SOPHiA DDM™ Platform to Further Research of Myeloid Disorders

/PRNewswire/ SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Hôpital Saint-Louis,.

United statesFrance generalBruno cassinatKevin puylaertCellular biology departmentMyeloid disordersMolecular diagnosticsManaging directorVitro diagnostic useSophia genetics

Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis

Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

John mascarenhasIcahn school of medicineTisch cancer instituteIcahn schoolMount sinaiBlood cancersMyeloid disorders

Dr Mascarenhas on the Rationale for the KRT-232-109 Study in Secondary Myelofibrosis

John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.

John mascarenhasIcahn school of medicineTisch cancer instituteIcahn schoolMount sinaiBlood cancersMyeloid disordersThe tisch cancer institute at mount sinaiOnclive tvMyeloproliferative neoplasms